Long-term BRAF(V600E) inhibition results in a spontaneous KRAS(G12D) mutation and increased epithelial to mesenchymal transition (EMT) in papillary thyroid cancer cells (PTC)

被引：0
|
作者：
Danysh, Brian P.
Cabanillas, Maria E.
Hofmann, Marie-Claude
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2933
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2933
引用
收藏
页数：3
相关论文
共 12 条
  • [1] Long-Term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model
    Danysh, Brian P.
    Rieger, Erin Y.
    Sinha, Deepankar K.
    Evers, Caitlin V.
    Cote, Gilbert J.
    Cabanillas, Maria E.
    Hofmann, Marie-Claude
    ONCOTARGET, 2016, 7 (21) : 30907 - 30923
  • [2] BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence
    Czarniecka, Agnieszka
    Oczko-Wojciechowska, Malgorzata
    Barczynski, Marcin
    GLAND SURGERY, 2016, 5 (05) : 495 - 505
  • [3] Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context
    Massimiliano Monticone
    Emanuela Biollo
    Massimo Maffei
    Alessandra Donadini
    Francesco Romeo
    Clelia Tiziana Storlazzi
    Walter Giaretti
    Patrizio Castagnola
    Molecular Cancer, 7
  • [4] Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context
    Monticone, Massimiliano
    Biollo, Emanuela
    Maffei, Massimo
    Donadini, Alessandra
    Romeo, Francesco
    Storlazzi, Clelia Tiziana
    Giaretti, Walter
    Castagnola, Patrizio
    MOLECULAR CANCER, 2008, 7 (1)
  • [5] BRAF V600E Mutation In Papillary Thyroid Cancer: Its Influence On Radioiodine Postsurgical Therapy - Preliminary Results
    Dominguez-Ayala, M.
    Minguez-Gabina, P.
    Exposito Rodriguez, A.
    Ortiz de Zarate, E. Rodeno
    Gutierrez Rodriguez, T.
    Barrios Trevino, B.
    Paja Fano, M.
    Gomez Palacios, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S157 - S157
  • [6] Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells
    Hou, Peng
    Liu, Dingxie
    Xing, Mingzhao
    ENDOCRINE-RELATED CANCER, 2011, 18 (06) : 687 - 697
  • [7] The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study
    Daliri, Mahdi
    Abbaszadegan, Mohammad Reza
    Bahar, Mostafa Mehrabi
    Arabi, Azadeh
    Yadollahi, Mona
    Ghafari, Azar
    Taghehchian, Negin
    Zakavi, Seyed Rasoul
    ENDOCRINE RESEARCH, 2014, 39 (04) : 189 - 193
  • [8] Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation
    Byeon, Hyung Kwon
    Na, Hwi Jung
    Yang, Yeon Ju
    Ko, Sooah
    Yoon, Sun Och
    Ku, Minhee
    Yang, Jaemoon
    Kim, Jae Wook
    Ban, Myung Jin
    Kim, Ji-Hoon
    Kim, Da Hee
    Kim, Jung Min
    Choi, Eun Chang
    Kim, Chang-Hoon
    Yoon, Joo-Heon
    Koh, Yoon Woo
    ONCOTARGET, 2017, 8 (01) : 596 - 609
  • [9] Does BRAF V600E Mutation Predict Aggressive Features in Papillary Thyroid Cancer? Results From Four Endocrine Surgery Centers
    Li, Carol
    Han, Patricia Aragon
    Lee, Kathleen C.
    Lee, Louis C.
    Fox, Amy C.
    Beninato, Toni
    Thiess, Michele
    Dy, Benzon M.
    Sebo, Thomas J.
    Thompson, Geoffrey B.
    Grant, Clive S.
    Giordano, Thomas J.
    Gauger, Paul G.
    Doherty, Gerard M.
    Fahey, Thomas J., III
    Bishop, Justin
    Eshleman, James R.
    Umbricht, Christopher B.
    Schneider, Eric B.
    Zeiger, Martha A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (09): : 3702 - 3712
  • [10] POU5F1B is responsible for the acquired resistance to dabrafenib in papillary thyroid cancer cells with the BRAF V600E mutation
    Li, Jun
    Yu, Yafeng
    ENDOCRINE, 2025, 87 (01) : 220 - 233
12